Arevalo J Fernando, Liu T Y Alvin
Retina Division, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Asia Pac J Ophthalmol (Phila). 2018 Jan-Feb;7(1):36-39. doi: 10.22608/APO.2017466. Epub 2017 Dec 27.
The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevacizumab as a preoperative, adjuvant therapy before vitrectomy for proliferative diabetic retinopathy.
玻璃体内抗血管内皮生长因子(抗VEGF)药物的出现彻底改变了糖尿病眼病的治疗方法。在此,我们报告泛美视网膜协作研究组(PACORES)开展的临床研究结果,特别关注玻璃体内注射贝伐单抗治疗糖尿病性黄斑水肿和增殖性糖尿病视网膜病变的疗效。我们还将讨论玻璃体内注射贝伐单抗在增殖性糖尿病视网膜病变玻璃体切除术前作为辅助治疗的应用。